Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03677375
Other study ID # TP-19466
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2018
Est. completion date February 4, 2019

Study information

Verified date April 2019
Source Masimo Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the concentration of hemoglobin within the subject's blood will be reduced in a controlled manner by administering fluids intravenously. The accuracy of a noninvasive hemoglobin sensor will be assessed by comparison to hemoglobin measurements from a laboratory analyzer.


Recruitment information / eligibility

Status Completed
Enrollment 173
Est. completion date February 4, 2019
Est. primary completion date February 4, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall.

- Hemoglobin value is greater than or equal to 11 g/dL at time of screening

- Baseline heart rate = 45 bpm and = 85 bpm.

- CO value = 2.0% FCOHb

- Subject has a physical status of ASA I or II (American Society of Anesthesiology Class I; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) as it applies to the systemic disease portion of the classification.

- Systolic Blood Pressure = 140 mmHg and Diastolic Blood Pressure = 90 mmHg.

- Subject is able to read and communicate in English and understands the study and risks involved.

Exclusion Criteria:

- Subject is pregnant

- Subject smokes (including e-cigarette use)

- Subject has a BMI > 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional.

- Subject has a history of fainting (vasovagal), blacking out or losing consciousness during or after a blood draw.

- Subject has open wounds, inflamed tattoos or piercings, or any visible healing wounds.

- Subject has known drug or alcohol abuse or uses recreational drugs.

- Subject has experienced a head injury with loss of consciousness within the last year.

- Subject has taken anticoagulant medication within the last 30 days.

- Subject has any chronic bleeding disorders (i.e. hemophilia).

- Subject has any history of a stroke, myocardial infarction, heart attack, or seizures.

- Subject has any cancer or history of cancer (not including skin cancer).

- Subject has a chronic neurological disease (i.e. multiple sclerosis, Huntington's disease).

- Subject has any cardiac dysrhythmias (i.e. atrial fibrillation) and has not received clearance from their physician.

- Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subject's level of consciousness.

- Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome

- Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator).

- Subject has taken opioid pain medication within 24 hours of start of study.

- Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles, etc.).

- Subject is taking medications known to treat any type of infectious disease.

- Subject has either signs or history of peripheral ischemia or carpal tunnel.

- Subject has had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, Urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery.

- Subject has symptoms of congestion, head colds, flu, or other illnesses

- Subject has donated blood within the last 2 weeks.

- Subject is claustrophobic or has generalized anxiety disorder.

- Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months.

- Subject has had a concussion within the last 12 months.

- Subject has chronic unresolved asthma, lung disease or respiratory disease.

- Subject is allergic to lidocaine, latex, adhesives, or plastic.

- Subject has heart conditions, insulin-dependent diabetes or uncontrolled hypertension.

- Subject has delivered vaginally, has had a pregnancy terminated, a miscarriage with hospitalization, or had a C-section within the last 6 months.

- Subject intends on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study that involves an arterial line.

- Discretion of investigator/study staff

Study Design


Related Conditions & MeSH terms


Intervention

Device:
INVSENSOR00026
Noninvasive pulse oximeter sensor

Locations

Country Name City State
United States Masimo Corporation Irvine California

Sponsors (1)

Lead Sponsor Collaborator
Masimo Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of Noninvasive Hemoglobin Sensor by Arms Calculation Accuracy will be determined by comparing the noninvasive hemoglobin measurement of the pulse oximeter to the hemoglobin value obtained from a blood sample and calculating the arithmetic root mean square (Arms) error value. In order to obtain the Arms value, the blood sample hemoglobin value is subtracted from the pulse oximeter hemoglobin value for a number of samples, the average of this difference is computed as the bias. The standard deviation of the differences is computed as the precision. The square root of the sum of the squares of bias and precision is computed as the Arms Error value. 1-5 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1